Potential therapeutic role of Tridham in human hepatocellular carcinoma cell line through induction of p53 independent apoptosis

BMC Complementary and Alternative Medicine

Shanthi Palanivelu²  Sachdanandam Panchanadham¹  Vijaya Ravinayagam²  Ravindran Jaganathan² 

[1] Department of Medical Biochemistry, Dr. ALM Post Graduate Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, Tamilnadu 600113, India;Department of Pathology, Dr. ALM Post Graduate Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, Tamilnadu 600113, India

关键词: Mitochondrial membrane potential (MMP);    Apoptosis;    p53;    Tridham;    Hepatocellular carcinoma (HCC);   

Others  :  1220517
DOI  :  10.1186/1472-6882-13-323

 received in 2013-06-23, accepted in 2013-11-15,  发布年份 2013

【 摘 要 】

Background

Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths reported worldwide. The incidence is higher in Asia and Africa, where there is greater endemic prevalence of hepatitis B and C. The devastating outcome of cancer can be minimized only by the use of potent therapeutic agents. Tridham (TD) has been acknowledged since olden days for its wide spectrum of biological properties and was used by traditional practitioners of Siddha and other indigenous systems of medicine. The present study aims at investigating the mechanistic action of TD by assessing the antiproliferative and pro-apoptotic effects on human hepatocellular carcinoma cell line (Huh7).

Methods

Cell viability and apoptosis assay using MTT analysis and trypan blue staining, DAPI staining, DNA fragmentation, cell cycle analysis, mitochondrial membrane potential, real-time reverse transcription-polymerase chain reaction, western blotting and immunofluorescence staining were determined in Huh7 cells.

Results

Viability studies of TD treated Huh7 cells showed an inhibition in cell growth in time and dose dependent manner. Chromatin condensation, DNA fragmentation and apoptotic bodies, which are structural changes characteristic of apoptosis, were found following TD treatment of Huh7 cells. DAPI staining and agarose gel electrophoresis confirmed the induction of apoptosis by TD. Cell cycle analysis of Huh7 cells treated with TD exhibited a marked accumulation of cells in the sub-G1 phase of the cell cycle in a dose dependent manner. Immunofluorescent staining for Ki-67 showed a higher level of expression in untreated cells as compared to TD treated cells. We observed a significant loss in the mitochondrial membrane potential and the release of cytochrome c into the cytosol in TD treated cells. Down regulation of Bcl-2, up regulation of Bax and Bad as well as activation of caspases-3 and 9 were also observed. The p53 gene expression was found to be unaltered in TD treated cells.

Conclusion

These results suggest that TD induces apoptosis of Huh7 cells through activation of Bax and triggered caspase cascade, independent of p53 function. This study throws light on the mechanistic action of TD in triggering apoptosis in Huh 7 cells.

【 授权许可】

   
2013 Jaganathan et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: Cancer statistics. CA Cancer J Clin 2004, 54(1):8-29.
• [2]Irfan A, Dileep NL: Malignant tumors of liver. Surgery 2006, 25:34-41.
• [3]Röcken C, Carl-McGrath S: Pathology and pathogenesis of hepatocellular carcinoma. Dig Dis 2001, 19(4):269-278.
• [4]Escarcega RO, Fuentes-Alexandro S, Garcia-Carrasco M, Gatica A, Zamora A: The transcription factor nuclear factor-kappa B and cancer. Clin Oncol 2007, 19(2):154-161.
• [5]Tascilar M, de Jong FA, Verweij J, Mathijssen RH: Complementary and alternative medicine during cancer treatment: beyond innocence. Oncologist 2006, 11(7):732-741.
• [6]Norbury CJ, Hickson ID: Cellular responses to DNA damage. Annu Rev Pharmacol Toxicol 2001, 41:367-401.
• [7]Salami S, Karami-Tehrani F: Biochemical studies of apoptosis induced by tamoxifen in estrogen receptor positive and negative breast cancer cell lines. Clin Biochem 2003, 36(4):247-253.
• [8]Riedl SJ, Salvesen GS: The apoptosome: signaling platform of cell death. Nature Rev Mol Cell Biol 2007, 8(5):405-413.
• [9]Spierings D, McStay G, Saleh M, Bender C, Chipuk J, Maurer U, Green DR: Connected to death: the (unexpurgated) mitochondrial pathway of apoptosis. Sci Signal 2005, 310(5745):66.
• [10]Breuhahn K, Longerich T, Schirmacher P: Dysregulation of growth factor signalling in human hepatocellular carcinoma. Oncogene 2006, 25(27):3787-3800.
• [11]Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, Rapaccini G, Del Poggio P, Di Nolfo MA, Benvegnu L, Zoli M, Borzio F, Bernardi M, Trevisani F: Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 2006, 101(3):524-532.
• [12]Chipuk JE, Green DR: How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol 2008, 18(4):157-164.
• [13]Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nature Rev Genet 2002, 3(6):415-428.
• [14]Ogunleye D, Ibitoye S: Short communication: studies of antimicrobial activity and chemical constituents of Ximenia americana. Trop J Pharm Res 2005, 2(2):239-241.
• [15]Auddy B, Ferreira M, Blasina F, Lafon L, Arredondo F, Dajas F, Tripathi PC, Seal T, Mukherjee B: Screening of antioxidant activity of three Indian medicinal plants, traditionally used for the management of neurodegenerative diseases. J Ethnopharmacol 2003, 84:131-138.
• [16]Shanmugavelan A, Sundararajan A (Eds): Siddhar’s Source of Longevity and Kalpa Medicine in India. Madras (now Chennai): Directorate of Indian medicine and homoeopathy; 1992.
• [17]Ravinayagam V, Jaganathan R, Panchanadham S, Palanivelu S: Potential antioxidant role of tridham in managing oxidative stress against Aflatoxin-B1-induced experimental hepatocellular carcinoma. Int J Hepatol 2012, 2012:1-9.
• [18]Kim HG, Cho JH, Jeong EY, Lim JH, Lee SH, Lee HS: Growth-inhibiting activity of active component isolated from Terminalia chebula fruits against intestinal bacteria. J Food Prot 2006, 69(9):2205-2209.
• [19]Bonjar GH: Inhibition of Clotrimazole-resistant Candida albicans by plants used in Iranian folkloric medicine. Fitoterapia 2004, 75(1):74-76.
• [20]Sabu M, Kuttan R: Anti-diabetic activity of medicinal plants and its relationship with their antioxidant property. J Ethnopharmacol 2002, 81(2):155-160.
• [21]Cheng HY, Lin TC, Yu KH, Yang CM, Lin CC: Antioxidant and free radical scavenging activities of Terminalia chebula. Bio Pharm Bull 2003, 26(9):1331-1335.
• [22]Saleem A, Husheem M, Härkönen P, Pihlaja K: Inhibition of cancer cell growth by crude extract and the phenolics of Terminalia chebula retz. fruit. J Ethnopharmacol 2002, 81(3):327-336.
• [23]Tasduq S, Singh K, Satti N, Gupta D, Suri K, Johri R: Terminalia chebula (fruit) prevents liver toxicity caused by sub-chronic administration of rifampicin, isoniazid and pyrazinamide in combination. Hum Exp Toxicol 2006, 25(3):111-118.
• [24]Lee HS, Jung SH, Yun BS, Lee KW: Isolation of chebulic acid from Terminalia chebula Retz. and its antioxidant effect in isolated rat hepatocytes. Arch Toxicol 2007, 81(3):211-218.
• [25]Grover IS, Bala S: Antimutagenic activity of Terminalia chebula (myroblan) in Salmonella typhimurium. Ind J Exp Biol 1992, 30(4):339-341.
• [26]Kamei H, Koide T, Hashimoto Y, Kojima T, Hasegawa M: Tumor cell growth suppression by tannic acid. Cancer Biother Radiopharm 1999, 14(2):135-138.
• [27]Gandhi NM, Nair CK: Radiation protection by Terminalia chebula: some mechanistic aspects. Mol Cell Biochem 2005, 277(1–2):43-48.
• [28]Kuhar M, Imran S, Singh N: Curcumin and quercetin combined with cisplatin to induce apoptosis in human laryngeal carcinoma hep-2 cells through the mitochondrial pathway. J Cancer Mol 2007, 3:121-128.
• [29]Gaurav S, Navneet N, Sandeep R, Preeti S, Shwali S, Amit P, Reni K: Elaeocarpus sphaericus: medical and scientific facts. Der Pharmacia Lettre 2010, 2:297-306.
• [30]Ray AB, Chand L, Pandey VB: Rudrakine, a new alkaloid from Elaeocarpus ganitrus. Phytochemistry 1976, 18:700-701.
• [31]Chand L, Dasgupta S, Chattopadhyay SK, Ray AB: Chemical investigation of some Elaeocarpus species. Planta Med 1977, 32(06):197-199.
• [32]Hardy S, El-Assaad W, Przybytkowski E, Joly E, Prentki M, Langelier Y: Saturated fatty acid-induced apoptosis in MDA-MB-231 breast cancer cells. A role for cardiolipin. J Biol Chem 2003, 278(34):31861-31870.
• [33]Ji J, Zhang L, Wang P, Mu YM, Zhu XY, Wu YY, Yu H, Zhang B, Chen SM, Sun XZ: Saturated free fatty acid, palmitic acid, induces apoptosis in fetal hepatocytes in culture. Experimental and toxicologic pathology 2005, 56(6):369-376.
• [34]Sharma N, Garg V, Paul A: Antihyperglycemic, antihyperlipidemic and antioxidative potential of Prosopis cineraria bark. Ind J Clin Biochem 2010, 25(2):193-200.
• [35]Chopra RN, Nayar SL, Chopra IC: In: Glossary of Indian Medicinal Plants. New Delhi: Council for Scientific and Industrial Research; 1956:204.
• [36]Malik A, Kalidhar SB: Phytochemical examination of Prosopis cineraria L. (druce) leaves. Indian J Pharm Sci 2007, 69(4):576-578.
• [37]Ravinayagam V, Jaganathan R, Panchanadham S, Palanivelu S: Cytotoxic effect of tridham (TD) against human HepG2 Cell line: isolation and characterization of 3, 4, 5-trihydroxybenzoic acid from aqueous extract of TD. IJDDHR 2012, 2(2):371-385.
• [38]Chen HM, Wu YC, Chia YC, Chang FR, Hsu HK, Hsieh YC, Chen CC, Yuan SS: Gallic acid, a major component of Toona sinensis leaf extracts, contains a ROS-mediated anti-cancer activity in human prostate cancer cells. Cancer Lett 2009, 286(2):161-171.
• [39]Kugawa F, Arae K, Ueno A, Aoki M: Buprenorphine hydrochloride induces apoptosis in NG108-15 nerve cells. Eur J Pharmacol 1998, 347(1):105-112.
• [40]Yokozawa T, Dong E: Role of ginsenoside-Rd in cisplatin-induced renal injury: special reference to DNA fragmentation. Nephron 2001, 89:433-438.
• [41]Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193(1):265-275.
• [42]Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, Durnez A, Demetris AJ, Thorgeirsson SS: Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004, 40(3):667-676.
• [43]Thomas MB, Zhu AX: Hepatocellular carcinoma: the need for progress. J Clin Oncol 2005, 23(13):2892-2899.
• [44]Patwardhan B: Ethnopharmacology and drug discovery. J Ethnopharmacol 2005, 100(1):50-52.
• [45]Saller R, Pfister-Hotz G, Iten F, Melzer J, Reichling J: Iberogast: a modern phytotherapeutic combined herbal drug for the treatment of functional disorders of the gastrointestinal tract (dyspepsia, irritable bowel syndrome)–from phytomedicine to” evidence based phytotherapy.“A systematic review. Forsch Komplementarmed Klass Naturheilkd 2002, 9(Suppl 1):1-20.
• [46]Fang X, Phoebe CH Jr, Pezzuto JM, Fong HH, Farnsworth NR, Yellin B, Hecht SM: Plant anticancer agents, XXXIV. Cucurbitacins from Elaeocarpus dolichostylus. J Nat Prod 1984, 47(6):988-993.
• [47]Huang GY, Zhang Y, Zhang Q, Zhang B, Wen LP: Vacuolization and apoptosis induced by nano-selenium in HeLa cell line. Sci China Chem 2010, 53(11):2272-2278.
• [48]Hsu S, Singh B, Schuster G: Induction of apoptosis in oral cancer cells: agents and mechanisms for potential therapy and prevention. Oral Oncol 2004, 40(5):461-473.
• [49]Stoner GD, Mukhtar H: Polyphenols as cancer chemopreventive agents. J Cell Biochem 2004, 59(22):169-180.
• [50]Yang CS, Wang ZY: Tea and cancer. J Natl Cancer Inst 1993, 85(13):1038-1049.
• [51]Danial NN, Korsmeyer SJ: Cell death: critical control points. Cell 2004, 116(2):205-219.
• [52]Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith-Sorensen B, Montesano R, Harris CC: Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 1994, 22(17):3551-3555.53.
• [53]Wallace HM, Fraser AV, Hughes A: A perspective of polyamine metabolism. Biochem J 2003, 376(1):1-14.
• [54]Saraste A, Pulkki K: Morphologic and biochemical hall mark of apoptosis. Cardiovasc Res 2000, 45(3):528-537.
• [55]Gilmore AP, Metcalfe AD, Romer LH, Streuli CH: Integrin-mediated survival signals regulate the apoptotic function of Bax through its conformation and subcellular localization. J Cell Biol 2000, 149(2):431-446.
• [56]Khaled AR, Kim K, Hofmeister R, Muegge K, Durum SK: Withdrawal of IL-7 induces Bax translocation from cytosol to mitochondria through a rise in intracellular pH. Proc Natl Acad Sci USA 1999, 96(25):14476-14481.
• [57]Nomura M, Shimizu S, Ito T, Narita M, Matsuda H, Tsujimoto Y: Apoptotic cytosol facilitates Bax translocation to mitochondria that involves cytosolic factor regulated by Bcl-2. Cancer Res 1999, 59(21):5542-5548.
• [58]Tremblais K, Oliver L, Juin P, Thérese Le Cabellec M, Meflah K, Vallette FM: The C-terminus of bax is not a membrane addressing/anchoring signal. Biochem Biophys Res Commun 1999, 260(3):582-591.
• [59]Han YH, Park WH: Growth inhibition in antimycin A treated-lung cancer Calu-6 cells via inducing a G1 phase arrest and apoptosis. Lung cancer 2009, 65(2):150-160.
• [60]Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC: Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA 1998, 95(9):4997-5002.
• [61]Budihardjo I, Oliver H, Lutter M, Luo X, Wang X: Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 1999, 15:269-290.
• [62]Takahashi K, Loo G: Disruption of mitochondria during tocotrienol-induced apoptosis in MDA-MB-231 human breast cancer cells. Biochem Pharmacol 2004, 67(2):315-324.
• [63]Zimmermann KC, Green DR: How cells die: apoptosis pathways. J Allergy Clin Immunol 2001, 108(4):S99-S103.
• [64]Bose I, Ghosh B: The p53-MDM2 network: from oscillations to apoptosis. J Biosci 2007, 32(5):991-997.
• [65]Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992, 356(6366):215-221.
• [66]Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA: Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994, 4(1):1-7.
• [67]Giaccia AJ, Kastan MB: The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 1998, 12(19):2973-2983.
• [68]Lohrum MA, Vousden KH: Regulation and activation of p53 and its family members. Cell Death Differ 1999, 6(12):1162-1168.
• [69]Jin S, Levine AJ: The p53 functional circuit. J Cell Sci 2001, 114(23):4139-4140.
• [70]Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC: Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991, 350(6317):427-428.
• [71]Kuwajerwala N, Cifuentes E, Gautam S, Menon M, Barrack ER, Reddy GP: Resveratrol induces prostate cancer cell entry into s phase and inhibits DNA synthesis. Cancer Res 2002, 62(9):2488-2492.
• [72]Masuda M, Suzui M, Weinstein IB: Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2001, 7(12):4220-4229.
• [73]D’Errico A, Grigioni WF, Fiorentino M, Baccarini P, Grazi GL, Mancini AM: Overexpression of p53 protein and Ki67 proliferative index in hepatocellular carcinoma: an immunohistochemical study on 109 Italian patients. Pathol Int 1994, 44(9):682-687.
• [74]Nakanishi K, Sakamoto M, Yamasaki S, Todo S, Hirohashi S: Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 2005, 103(2):307-312.
• [75]Noguchi M, Yokoyama M, Watanabe S, Uchiyama M, Nakao Y, Hara K, Iwasaka T: Inhibitory effect of the tea polyphenol, (−)-epigallocatechin gallate, on growth of cervical adenocarcinoma cell lines. Cancer Lett 2006, 234(2):135-142.